EGFR and neoplasm: EGFR biosensing was first described by the Matsuda group more than a decade ago.9 However, the preclinical imaging of EGFR heterogeneity in animal models has been hampered by difficulties in targeting an EGFR biosensor to tumour cells in vivo.